Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. H.J. (Hiddo) Lambers Heerspink

Publicaties

Authors' Reply: Effects of Zibotentan and Dapagliflozin on Fluid Retention in Patients with CKD: Need More Evidence

Compositions and methods for treating and preventing kidney disease

Endothelin receptor antagonists in chronic kidney disease

Improving Patient Selection in Clinical Trials: Should We Start Using the Pretrial eGFR Decline as Risk Enrichment Criterion?

Quantitative aortic Na[18F]F positron emission tomography computed tomography as a tool to associate vascular calcification with major adverse cardiovascular events

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

Sex differences in response to the endothelin receptor antagonist atrasentan in individuals with type 2 diabetes and chronic kidney disease: a post hoc analysis of the SONAR trial

Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials

Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy

The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease

Pers/media

Diabetesmedicijn Ozempic heeft ook positief effect bij chronische nierschade

Semaglutide in patinenten met nierziekte

BioCity announces its endothelin receptor A selective antagonist SC0062 met the ...

Zibotentan, Dapagliflozin Combo Further Reduces Albuminuria in CKD

New Hope for Treating Chronic Kidney Disease in Type 1 Diabetes

First-in-class treatment delivers major advance for incurable kidney disease

First-in-Class Treatment Brings Major Breakthrough for Incurable Kidney Disease